Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
Vaccine
; 31(51): 6136-43, 2013 12 09.
Article
en En
| MEDLINE
| ID: mdl-23850416
Palabras clave
(S)AE; (serious) adverse event; 95% CI; 95% confidence interval; AS04; ATP; Alum; ELISA; ELISA units; EU; GMC; GSK; Genital herpes; GlaxoSmithKline; HAV; HSV; HSV vaccine; HSV-1; HSV-2; Herpes simplex virus type 1; Herpes simplex virus type 2; IU; IgG; MPL; NOCD; OD; Safety; TVC; according to protocol; aluminium hydroxide; aluminium hydroxide and 3-O-deacylated monophosphoryl lipid A adjuvant system; enzyme-linked immunosorbent assay; gD2; geometric mean concentration; hepatitis A vaccine; herpes simplex virus; herpes simplex virus type 1; herpes simplex virus type 2; herpes simplex virus type 2 glycoprotein D; immunoglobulin G; international units; monophosphoryl lipid A; new onset chronic diseases; optical density; total vaccinated cohort
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Herpes Genital
/
Vacunas contra Herpesvirus
/
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos
Tipo de estudio:
Clinical_trials
Límite:
Adolescent
/
Child
/
Female
/
Humans
Idioma:
En
Año:
2013
Tipo del documento:
Article